Thomas K. Equels, CEO, President at HEMISPHERX BIOPHARMA INC (HEB), bought 48,000 shares at $0.12 ($6K) on 2016-07-08, disclosed to the SEC on 2016-07-08.
Open-market purchase of $6k HEB by CEO, President. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| AIM | BUY | 2020-12-17 | $25K | — | Filing → |
| AIM | BUY | 2020-09-03 | $25K | — | Filing → |
| AIM | BUY | 2020-08-21 | $25K | — | Filing → |